Development of orally disintegrating tablets comprising controlled-release multiparticulate beads.

Melperone is an atypical antipsychotic agent that has shown a wide spectrum of neuroleptic properties, particularly effective in the treatment of senile dementia and Parkinson's-associated psychosis, and is marketed in Europe as an immediate-release (IR) tablet and syrup. An orally disintegrating tablet (ODT) dosage form would be advantageous for patients who experience difficulty in swallowing large tablets or capsules or those who experience dysphagia. Controlled-release (CR) capsule and ODT formulations containing melperone HCl were developed with target in vitro release profiles suitable for a once-daily dosing regimen. Both dosage forms allow for the convenient production of dose-proportional multiple strengths. Two ODT formulations exhibiting fast and medium release profiles and one medium release profile capsule formulation (each 50 mg) were tested in vivo using IR syrup as the reference. The two medium release formulations were shown to be bioequivalent to each other and are suitable for once-daily dosing. Based on the analytical and organoleptic test results, as well as the blend uniformity and in-process compression data at various compression forces using coated beads produced at one-tenth (1/10) commercial scale, both formulations in the form of CR capsules and CR ODTs have shown suitability for progression into further clinical development.

Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy.

PURPOSE: Photodynamic therapy (PDT) is an emerging, minimally invasive therapy for prostate cancer that depends on the sequestration of a photosensitizing drug within targeted tissue. The photosensitizer is subsequently activated by light of a specific wavelength, resulting in destruction of the targeted tissue. Successful treatment requires knowledge of the optical properties of the target tissue, a critical element for therapy. MATERIALS AND METHODS: Adult canines were injected with tin etiopurpurin dichloride (1.0 mg/kg) as a liposome emulsion vehicle in saline 24 hours prior to light treatment. Laser light was delivered to the prostate via a 400 microm optical fiber fitted with a 2.0 cm cylindrical diffuser and optical properties of the prostate were measured. RESULTS: In this study we determined the attenuation coefficient and critical fluence in the canine prostate. Our studies shown that the attenuation coefficient is not uniform but higher at the base (average for all animals 2.59 to 2.79 cm-1) than in the mid section or apex of the prostate (1.71 to 1.90 cm-1). Significant differences among dogs (0.11 to 12.70 cm-1) were found. In some cases we observed a fluctuation of the attenuation coefficient during treatment. We also established experimentally the minimum energy (1449 mJ/cm2) needed (critical fluence) to produce necrosis. Experimentally establishing the values of effective attenuation and critical fluence is necessary to predict the area of ablation during PDT and protect surrounding organs from over treatment. CONCLUSIONS: Based on our results it is evident that for PDT of the prostate to be successful the optical parameters of the prostate must be measured and monitored during treatment. We suggest that the optimum way of doing this is real-time computerized monitoring combined with simulation PDT.

Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation.

PURPOSE: This study was aimed at the synthesis, formulation and in vitro evaluation of folate receptor (FR)-targeted solid-lipid nanoparticles (SLNs) as a carrier for a lipophilic derivative of the photosensitizer hematoporphyrin (Hp), in FR-overexpressing tumor cells. MATERIALS AND METHODS: FR-targeted hematoporphyrin-stearylamine (HpSa) SLN composed of Triolein:Egg-phosphatidylcholine (EPC):Tween-80 (T-80) (64:25:10), with 0.5 mole % of folate-polyethyleneglycol-cholesterol (FPC) or polyethyleneglycol-distearoylphosphatidylethanolamine (PEG-DSPE), were prepared by ethanol injection method. Stability of the SLN was monitored by changes in particle size at 4 degrees C and drug retention at various time points. Cellular uptake and IC50 values of the FR-targeted formulations were determined in vitro in the FR (+) KB cells. RESULTS: Stable targeted SLNs were prepared by ethanol injection encapsulating greater than 95 percent of 5 mole % of HpSa, having a mean diameter < 200 nm. In vitro cytotoxicity assay on the FR-targeted SLN gave IC50 of 1.57 microM in KB cells and non-targeted SLNs gave an IC50 of 5.17 microM. FR selectivity was confirmed by fluorescence microscopy. CONCLUSION: FR-targeted SLNs incorporating the lipophilic drug HpSa were capable of specific receptor binding in cultured KB cells, which warrants further investigation.

A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug.

PURPOSE: The anticancer drug paclitaxel has poor aqueous solubility and is difficult to formulate in a lipid-based formulation due to its limited lipid solubility. Paclitaxel-7-carbonyl-cholesterol (Tax-Chol), a prodrug of paclitaxel with increased lipophilicity, was therefore synthesized and evaluated for incorporation into a lipid nanoparticle (LN) formulation, which also contained folate-polyethylene glycolcholesterol (f-PEG-Chol) as a ligand that targets the tumor marker folate receptor (FR). This novel formulation was designed for prolonged systemic circulation and selective targeting of tumor cells with amplified FR expression. METHODS: Tax-Chol was synthesized. FR-targeted LNs, composed of distearoyl phosphatidylcholine (DSPC)/triolein/Chol oleate/PEG-Chol/f-PEG-Chol (40:40:18:2.0:0.5, mole/mole), were then prepared by solvent dilution followed by diafiltration. FR-targeted LNs containing Tax-Chol were then evaluated for cytotoxicity in KB, a human oral carcinoma cell line, and M109, a murine lung carcinoma cell line, both of which are FR(+) and in FR(-) Chinese hamster ovary (CHO) cells. Furthermore, tumor growth inhibition and animal survival in response to treatment with FR-targeted LNs and control formulations were evaluated in BALB/c mice bearing subcutaneously engrafted M109 tumors. RESULTS: The LNs had a mean diameter of 130 nm and Tax-Chol incoporation efficiency of greater than 90% and exhibited excellent colloidal stability. FR-targeted LNs showed greater uptake and cytotoxicity in FR(+) KB and M109 cells than nontargeted LNs. Furthermore, treatment of mice bearing M109 tumors with FR-targeted LNs resulted in significantly greater tumor growth inhibition and animal survival compared to treatment with nontargeted LNs or paclitaxel formulated in Cremophor EL. CONCLUSION: FR-targeted LNs containing Tax-Chol are a promising novel formulation for the treatment of FR(+) tumors and further preclinical studies are warranted.

Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy.

BACKGROUND: The folate receptor is amplified in a variety of human tumors including over 90% of ovarian carcinoma. FR-targeted liposomes have previously been used by us to selectively deliver entrapped boron-containing compounds to tumor cells for neutron capture therapy (NCT). In the present study we have evaluated the delivery of Na3(B20H17NH3), which has been loaded into FR-targeted liposomes, in mice bearing xenograft implants of FR (+) KB subcutaneous tumor. MATERIALS AND METHODS: Na3(B20H17NH3) was passively entrapped into FR-targeted liposomes, which were administered intravenously into nude mice bearing s.c. implants of the FR(+) human oral carcinoma KB cell line. Normal and tumor boron content was measured by direct current plasma-atomic emission spectroscopy. RESULTS: Mice that received FR-targeted liposomes containing boron showed the highest tumor boron levels at 24 hours (6.1 micrograms/g) and tumor/blood boron ratios continued to rise for up to 120 hours. CONCLUSION: Boron delivery via FR-targeted liposomes is feasible and potentially can improve tumor uptake compared to non-targeted liposomes, and may improve cellular and subcellular localization.

Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.

BACKGROUND: Doxorubicin can be loaded into preformed liposome by remote loading. Lyophilization of liposomes results in particle size increase and content leakage. Cryoprotectants have been used to improve the stability of liposomal formulations during lyophilization. Here we have developed a formulation kit for liposomal doxorubicin based on lyophilized liposomes incorporating these cryoprotectants. MATERIALS AND METHODS: Liposomes compared of egg phosphatidylcholine/cholesterol and containing either glucose or sucrose as a cryoprotectant were prepared by polycarbonate membrane extrusion. These were then loaded with doxorubicin by a pH-gradient-based remote loading procedure either before or after lyophilization and reconstitution. The loading efficiency of DOX was evaluated by gel-filtration chromatography. The effect of lyophilization on the stability of liposomal DOX was also evaluated. RESULTS: Cryoprotectants were effective in maintaining liposome size distribution but not drug retention during lyophilization. DOX loading efficiency of the reconstituted liposomes was near quantitative and comparable to that of freshly prepared liposomes. CONCLUSION: Liposomal doxorubicin can be produced and stored as a lyophilized kit that can be reconstituted without significant changes to critical formulation properties.

A folate receptor-targeted emulsion formulation for paclitaxel.

PURPOSE: This study was aimed at the formulation and an in vitro evaluation of folate receptor (FR)-targeted emulsions as carriers for the lipophilic drug paclitaxel, in FR-overexpressing tumor cells. MATERIALS AND METHODS: FR-targeted paclitaxel emulsions (< 100 nm) composed of Tween-80:triolein:cholesterol:oleic acid:egg-phosphatidylcholine (EPC) (10:30:19.5:30:10), with 0.5 mole % of folate-polyethyleneglycol-cholesterol or polyethyleneglycol-distearoylphosphatidylethanolamine (PEG-DSPE), were prepared by ethanol injection method. Stability of the emulsions was monitored by changes in particle size while at 4 degrees C and 25 degrees C, and drug retention at various time-points. IC50 of the FR-targeted formulations was determined in vitro in the FR+ KB cells. RESULTS: Stable targeted emulsions were prepared by ethanol injection encapsulating greater than 70 percent of paclitaxel, having a mean diameter < 100 nm. In vitro cytotoxicity assay on the FR-targeted emulsions gave IC50 of 0.13 microM in KB cells. There was a significant difference in the IC50 values between the targeted emulsions and those that were non-targeted. CONCLUSION: FR-targeted emulsions incorporating the lipophilic drug paclitaxel were capable of specific receptor binding in cultured KB cells and warrant further investigation in vivo. This article is the first report on an FR-targeted emulsion-type drug carrier. Furthermore, a novel mechanism for in vivo antitumor activity of nanoparticular formulations, such as these emulsions, that is based on their antiangiogenic effect is proposed.